FY2025 EPS Estimates for APLS Raised by Cantor Fitzgerald

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Research analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for shares of Apellis Pharmaceuticals in a research note issued to investors on Wednesday, July 2nd. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the company will post earnings per share of ($0.22) for the year, up from their prior estimate of ($2.38). Cantor Fitzgerald has a “Overweight” rating and a $44.00 price objective on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Cantor Fitzgerald also issued estimates for Apellis Pharmaceuticals’ FY2026 earnings at ($0.91) EPS.

Several other research firms also recently commented on APLS. Citigroup lowered their target price on shares of Apellis Pharmaceuticals from $49.00 to $41.00 and set a “buy” rating on the stock in a report on Thursday, May 22nd. Morgan Stanley boosted their price objective on shares of Apellis Pharmaceuticals from $25.00 to $26.00 and gave the company an “equal weight” rating in a research report on Wednesday. Raymond James Financial cut shares of Apellis Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and cut their price target for the stock from $75.00 to $52.00 in a report on Friday, May 9th. Scotiabank cut their price target on shares of Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating on the stock in a report on Thursday, May 8th. Finally, Wells Fargo & Company increased their target price on shares of Apellis Pharmaceuticals from $26.00 to $29.00 and gave the stock an “equal weight” rating in a report on Monday, June 2nd. Nine research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $39.79.

Apellis Pharmaceuticals Trading Up 0.9%

Shares of APLS stock opened at $17.99 on Friday. Apellis Pharmaceuticals has a 52-week low of $16.10 and a 52-week high of $42.47. The company has a debt-to-equity ratio of 2.76, a quick ratio of 3.62 and a current ratio of 4.08. The firm has a market capitalization of $2.26 billion, a PE ratio of -10.05 and a beta of 0.67. The stock has a fifty day simple moving average of $18.15 and a two-hundred day simple moving average of $23.52.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.38). The business had revenue of $149.90 million during the quarter, compared to analysts’ expectations of $197.61 million. Apellis Pharmaceuticals had a negative return on equity of 99.19% and a negative net margin of 28.83%. The business’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.54) EPS.

Institutional Trading of Apellis Pharmaceuticals

Several hedge funds have recently made changes to their positions in APLS. EverSource Wealth Advisors LLC lifted its stake in shares of Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after purchasing an additional 758 shares during the period. Assetmark Inc. grew its holdings in shares of Apellis Pharmaceuticals by 3,938.7% during the first quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock worth $27,000 after buying an additional 1,221 shares in the last quarter. Signaturefd LLC grew its holdings in shares of Apellis Pharmaceuticals by 357.2% during the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock worth $37,000 after buying an additional 918 shares in the last quarter. GF Fund Management CO. LTD. grew its holdings in shares of Apellis Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock worth $70,000 after buying an additional 573 shares in the last quarter. Finally, US Bancorp DE grew its holdings in shares of Apellis Pharmaceuticals by 70.0% during the fourth quarter. US Bancorp DE now owns 3,223 shares of the company’s stock worth $103,000 after buying an additional 1,327 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Insiders Place Their Bets

In related news, General Counsel David O. Watson sold 5,000 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $18.77, for a total transaction of $93,850.00. Following the completion of the sale, the general counsel owned 133,730 shares in the company, valued at $2,510,112.10. This represents a 3.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.50% of the stock is currently owned by corporate insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).